Detalhe da pesquisa
1.
Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
Lupus
; 31(8): 974-984, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35593174